sessions insert the material into a suitable vein. Lady Mary had great faith: 'there is no example of anyone that has died of it and you may believe I am very well satisfied of the safety of this experiment since I intend to try it on my dear little son'. Edward was variolated and he survived.
So impressed was Lady Mary that on return to England she set about persuading influential people to accept variolation in this country. This was no easy task, but being a determined woman she decided to persuade the King (George I) of the great advantages of variolation. She enlisted the help of the Princess of Wales, Sir Hans Sloane, President of the Royal Society and Dr Richard Meade, Physician to the Royal Household. There then followed what was probably the first 'clinical trial' in this country. Six condemned prisoners at Newgate Prison were offered a free pardon if they agreed to variolation. They accepted, they were variolated, and true to the King's promise they were given their pardon after their ordeal. The King's two grandchildren were then variolated, but there is no record of the King accepting the offerpossibly he had already had smallpox as the disease was rife in London at the time. Today, of course, such an experiment would be unthinkable. Even the Sovereign, or her physician, would probably have to hold a clinical trials' certificate from the Committee on Safety of Medicines and would have had to satisfy the local Ethical Committee.
Variolation was practised for over a century in England before being made illegal in 1840 and although there are no reliable records available for morbidity and mortality from smallpox in this country before 1870, variolation probably played some part towards controlling the disease.
Many details can be found in contempory records ofthe virtues ofvariolation. For example, James Woodforde in his 'Diary of a Country Parson 1758-1802' makes several references to the success of the procedure, but he adds a prayer '0 Lord send this Blessing of Health on them all' (Woodforde 1978)! Edward Jenner (I 749-1823) , the son of a clergyman, was born in Berkeley in Gloucestershire on 17 May 1749. He has been variously described as a pioneer who conquered smallpox, or as self-opinionated, misinformed, avaricious and difficult to cooperate with.
Jenner was well aware, from talking to patients in his practice at Sodbury, Gloucestershire of the belief that persons who had contracted cowpox, then an endemic but very mild disease transmitted from the udders of the cow to the milker, seldom, if ever, contracted the vastly more virulent disease, smallpox. Jenner records that his first case (Jenner 1798) , Joseph Merrett, an under-gardener to the Earl of Berkeley, often assisted in milking his master's cows. Several horses belonging to the farm began to have sore heels which Merrett frequently attended. In the year 1770 the cows became affected with cowpox and Merrett developed SOres on his hands with swellings and stiffness of the axillae. In April 1795, i.e. 25 years later, a general inoculation (variolation) took place but Merrett after repeated 'variolations' failed to develop what we would now call a 'take'. He was apparently resistant or immune. Between 1770 and 1796, Jenner observed and recorded the relationship between the cowpox and smallpox. Clearly, he believed that cowpox was smallpox of the cow, hence the title of his first 'Inquiry in the Causes and Effects of the Variolae Vaccinae' and hence the modem term 'vaccination' (from the Latin word vacca, a cow; derivative word vaccinus). Jenner originally believed that there was a link between a disease of horses called grease, which produced a swelling in the heel, and cowpox. In his Inquiry, he commented 'that the disease [cowpox] makes its progress from the horse to the nipple of the cow and from the cow to the human subject ... but what renders the cow-pox so extremely singular is that persons who have been thus affected are for ever secure from the infection of the smallpox; neither exposure to the variolous effluvia nor the insertion of the matter in the skin producing this distemper' (Jenner 1798 ).
Jenner continued his observations for many more years until he was reasonably certain of his facts, and then on 14 May 1796 he selected a healthy boy about eight years old for the purpose of inoculation of the cowpox (James Phipps, case XVII). The matter was taken from the sore of a dairy-maid, Sarah Neames (case XVI). The case history goes on to record that James Phipps developed typical cowpox lesions which healed in the usual fashion. Then on I July 1796, Jenner inoculated James with variolous matter with several incisions on both arms, but no disease followed. This was repeated several months later, 'but no sensible effect was produced on the constitution' (Jenner 1798) . Thus Jenner and James Phipps had made history, because many other 'cowpoxings' or 'vaccinations', as the new procedure was called, followed.
Jenner took up residence in London late in 1798 to complete his observations for presentation to the Royal Society, of which he was a Fellow. In fact, he was admonished by the President and advised 'to be more cautious and prudent' but he subsequently published his first Inquiry privately, and in 1799he published his 'Further Observations' (Jenner 1799) and in 1800 'A Continuation of Facts and Observations' (Jenner 1801) .
Whilst in London between 1798 and 1800,Jenner met many of the leading members of the medical profession: Mr Henry Cline ofSt Thomas's Hospital, Dr Woodville, Physician to the Smallpox and Inoculation Hospital, and Dr George Pearson ofSt George's Hospital who later took over from Woodville at the Smallpox Hospital, then located at Battle Bridge, near to the present site of King's Cross Station. Supplies of cowpox lymph were handed to Cline and to Woodville, although according to Razzell (1977) , by 1799 difficulties were being experienced with Jenner's lymph as the number of 'takes' was reduced. As a result, Woodville obtained a new supply oflymph from a dairy farm in Gray's Inn Road which, when used at the Smallpox Hospital, gave rise to lesions entirely different from the cowpox used by Jenner. They were more severe and in nearly all cases were disseminated; in some cases several hundred pustules were produced (Jenner & Woodville 1800). Razzell (1977) suggests that Woodville experienced problems of contamination with the different number of strains that he introduced into the London Smallpox Hospital. I think it is more likely that it was the deliberate practice of variolation after vaccination which led to the contamination, coupled with the fact that these vaccinations were carried out in an environment which must have been laden with smallpox virus. We now know that the pox viruses are extremely stable agents and will survive in dust for many months, quite unlike any other virus. Moreover, these events took place 100 years before the cause of smallpox was known and at least 150years before the properties of the pox viruses came to be appreciated (Downie 1959) .
In 1806, the Chancellor of the Exchequer presented a petition to the King 'that the Royal Colleges of Physicians should enquire into the state of vaccine inoculation in the Kingdom' (see Dudgeon 1963) .They reported favourably only nine months later and the following year the National Vaccine Establishment was set up in London under Royal Warrant for the collection, supervision and distribution of vaccine lymph (Hansard 1808). Jenner died in 1823, aged 74, before the Vaccination Acts came into force, somewhat embittered depending on which biographer you choose to read (Baron 1838 , Camac 1909 , Razzell 1977 . The last biographer is particularly critical of Jenner: 'the heroism with which medical history has portrayed Jenner has all the hallmarks of a medical myth, although some might prefer to see it as one of Kuhn's paradigms of science'. I disagree with this view entirely. There is no question whatsoever that Jenner recognized the protective effect of cowpox over smallpox although he was not the first to do so (see Dudgeon 1963) , but he does seem to have been the first to recognize the significance of these findings. The myth, if there be one, lies in the last part of the story, the origin of smallpox vaccine or what is now called calf lymph. Jenner started with cowpox virus, but the vaccinators at the end of the nineteenth century certainly ended up with a different biological product.
Between 1840 and 1898 at least five Acts of Parliament were passed giving statutory authority regarding vaccination. The first Act of 1840 recommended vaccination and made variolation illegal. The 1853 Act made vaccination compulsory, which was a dismal failure from the start. The 1858and 1874Acts modified the law on compulsory vaccination and on the system of penalties. By far the most important, however, was the 1898Act which incorporated many of the provisions recommended by the Royal Commission on Vaccination of 1889, including the details of preparation of lymph and the use of glycerine to reduce the number of bacteria and many other details recommended by the famous Dr Monckton Copeman. This Act operated for a further 50 years until compulsory vaccination was rescinded in 1947.
Smallpox vaccines have been in use in one form or another for just upon 200 years, but the remarkable thing is that the true origin of vaccine lymph in use today, certainly as far as the UK is concerned, is not known. Much has been written about this subject but most of this is based on speculation and not upon fact. We can be reasonably certain that in the nineteenth century, humanized lymph obtained from arm-to-arm transfer was the main source of supply, but whether the material was cowpox, or cowpox contaminated with smallpox, is not clear. I believe that contamination did occur, largely due to the unnecessary practice of postvaccination variolation, By 1877 when the Animal Vaccine Establishment was opened at 95 Lambs Conduit Street, London (Dudgeon 1963) , there was a progressive move to adopt calf lymph and then in 1898 glycerinated calf lymph. The current strain of lymph produced by the Lister Institute in Chelsea in 1907 is reputed to have come from a Prussian soldier with smallpox in the war of 1870 (Hutchinson 1947 , Dudgeon 1963 ), but as Razzell (1977) rightly points out, there is no confirmation of this. What then is the origin of vaccine lymph, or more specifically of vaccinia virus used for vaccine production in this country? Is it derived from smallpox, from cowpox or from some other source? The simple answer is we do not know and probably never shall, but it is an intriguing thought that for years we have been using a vaccine the origin of which is so obscure. Baxby (1977) has written extensively on this subject and tends to favour the concept that vaccinia virus was used by the early vaccinators, but that the natural host in which it was maintained has not been identified. Could vaccinia have been derived from grease, or nineteenth century horsepox? But again this is mere speculation. I favour Baxby's earlier view that vaccinia has no natural host other than man, that it is a laboratory hybrid produced by genetic recombination of smallpox and cowpox viruses. We now know that genetic recombination can be achieved quite readily with influenza viruses in the laboratory, and probably in nature as well; and indeed the same can occur with the pox viruses (Bedson &Dumbell1964). Baxby (1977) has suggested that cowpox may be a misnomer as some of the cases investigated by him had no obvious contact with cattle. On the other hand, the cases of human cowpox that I have investigated have had a definite association with infected cattle and, moreover, the lesions produced by the three related pox viruses -smallpox, cowpox and vaccinia -all produce quite distinct lesions when inoculated on the chorioallantoic membrane of fertile eggs.
Measles was another severe epidemic scourge of great severity in the eighteenth century. In 1758, Francis Home of Edinburgh wrote: 'Considering how destructive this disease is, in some seasons; considering how many die, even in the mildest epidemical constitution; considering how it hurts the lungs and eyes; I thought I should do no small service to mankind, if I could render this disease more mild and safe, in the same way as the Turks have taught us to mitigate the smallpox. I suspect'strongly, that the cough, often so harassing, even in the mildest kind, was produced by receiving the infection mostly by the lungs; and I hoped that this symptom would abate considerably, if I could find a method of communicating the infection by the skin alone. I could not find a sufficient quantity of scaly matter, after the measles were dried, to serve my purpose. I then applied directly to the magazine of all epidemic diseases, the blood. I chused to take it from the most feverish patients. It was applied to an incision in each arm as is done in the small-pox. It appears that the inoculated measles are a much milder disease than the natural as the former are not attended with that degree of fever which precedes the latter; nor with the cough, want of rest, and other inflammatory complaints ... Whence does this arise?' (Home 1758).
The observations of Home are quite fascinating bearing in mind that he was writing some 200 years before Enders & Peebles (1954) were able to develop an attenuated vaccine deriVed from the blood of a child with measles and which produced an illness generally milder than the natural disease. Moreover, he obviously recognized that measles was a respiratory disease and not a skin disease, and that bloodstream dissemination was an essential element of the pathogenesis of measles.
Following the great discoveries of Pasteur, Koch and the other famous European scientists of the mid-nineteenth century, the causes of many of the common communicable diseases such as typhoid, cholera and diphtheria were established by the tum of the century. The discovery of viruses, the so-called filtrable or ultramicroscopic agents, followed during the first part of the present century and by 1930 the causation of smallpox, measles, poliomyelitis, yellow fever, rubella and others had been established. Surprisingly, it took many years between the discovery of the prophylactic properties of diphtheria and tetanus antitoxin in the late 1890s and the introduction of active immunization with the respective toxoids during the 1939-45 war. Possibly in retrospect, this was just as well, otherwise some of the disasters which have occurred with some of the earlier immunological products might have been more numerous (see Wilson 1967) . Fear of paralysis from poliomyelitis 30 years ago was understandably very great and, not surprisingly, reports that a protective vaccine had been developed were heralded with enthusiasm. The two vaccines, developed by Kolmer (1935) and Brodie (1935) , were prepared from spinal cord tissue of animals inoculated with a strain of poliovirus. This was almost certainly one strain of poliovirus (probably type 2) and the vaccine was used after inactivation by chemical treatment. As far as one can tell, there were virtually no safety tests, no standardization; and as a result of several paralytic illnesses in the vaccinees, the vaccines were wisely withdrawn.
The discovery by Enders, Weller and Robbins, in 1949 , that poliovirus could be grown in tissue and cell cultures was undoubtedly the most significant step forward in modem preventive medicine as it led to a new era of technological development for vaccine production, which has had such a profound effect in the control of poliomyelitis and many other viral infections in the past 25 years. Again one must issue a word of caution. Within three years of the isolation of poliovirus by Enders et al. (1949) an inactivated vaccine was submitted to a field trial in the United States. The trial, carried out in the US and evaluated by Dr Thomas Francis and his colleagues, was successful in that it established a degree of protection with the new vaccine, but the following year a further disaster occurred. Masses of doses of inactivated poliovaccine were released on to the market including some faulty batches from one manufacturer, Cutter Laboratories. As a result many people were severely paralysed and many died. This episode inevitably led to a loss of confidence which took a long time to restore, but on the benefit side it had a profound effect on the manufacture of bacterial and viral vaccines. From then on, manufacturers, governmental agencies, licensing authorities and anyone concerned with vaccine production had to comply to a new set of standards in which safety was the key word. The Cutter incident resulted from speed to get the vaccine on to the market and from negligence (Curran 1977 , Dudgeon 1978 . Speed should never be a factor in vaccine production, but safety always should be the top priority. As Perkins has so aptly stated (1969, 1973) , three questions have to be asked before an immunological product can be considered for use in human beings. First, where was the vaccine made and by whom; secondly, what were the results of tests for extraneous agents; and thirdly, how effective is the prophylactic agent in prevention of disease? I would add a fourth criterion of good manufacturing procedure, and that is consistency in good production.
Today, under the regulations of the Medicines Act of 1968, production of vaccines must conform to strict regulations and, to all intents and purposes, the seed virus or bacterium used to initiate the cultures from which the vaccine is prepared is probably the most important factor. This started with the development of the 170 strain for yellow fever vaccine, but has since been adapted for all new viral vaccines such as oral poliovaccine (OPV), measles and rubella vaccines. All new batches of vaccine have to be produced from a carefully prepared seed lot system which ensures purity of the vaccine. This, together with the careful selection of the cell substrate, has done more than anything else to ensure the safety and potency of vaccines currently in use (WHO 1966 , Perkins 1973 .
Some years ago, in a discussion of rabies vaccines prior to the introduction of the most recently developed tissue culture vaccine, Koprowski (1967) commented 'that rabies vaccines were indisputably the crudest biological products ever injected under the human skin'. I can think of others. Smallpox vaccine is one. In the British Pharmacopoeia of 1932 it states that 'smallpox vaccine is prepared with precautions to exclude bacterial contamination, asfar as possible' (my italics). A hundred years ago, there were two vaccines available for prevention of disease in human beings -smallpox and rabies vaccines. Now there are many more and that is not the end of the story. With modem technology it is now possible, to produce a prophylactic product, vaccine or immunoglobulin, against virtually any infectious disease, once the causative agent has been isolated. Some of the newer vaccines awaiting clinical trials or permission for clinical trials are shown in Table 1 . I very much doubt if this list, produced last year, is now complete.
